Expertise in
26
conditions

Dr. Mohamad Khawandanah

Hematology
Ou Health Partners Inc
800 Ne 10th St, Ouhp Stephenson Cancer C, 
Oklahoma City, OK 
13 Years of Experience
Expertise in
26
conditions
Ou Health Partners Inc
800 Ne 10th St, Ouhp Stephenson Cancer C, 
Oklahoma City, OK 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mohamad Khawandanah is a Hematologist in Oklahoma City, Oklahoma. Dr. Khawandanah has been practicing medicine for over 13 years is highly rated in 26 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Hodgkin Lymphoma, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 24 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in OK
Hospital Affiliations
Mercy Hospital Oklahoma City, Inc
O U Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

OU HEALTH PARTNERS INC
800 Ne 10th St, Ouhp Stephenson Cancer C, Oklahoma City, OK 73104
Other Locations
OU HEALTH PARTNERS INC
1100 Ne 13th St, Ouhp Child Study Center, Oklahoma City, OK 73117
OU HEALTH PARTNERS INC
1200 Childrens Ave, Suite B770, Oklahoma City, OK 73104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Dasatinib, Imatinib Mesylate, Nilotinib, Pembrolizumab
Study Phase: Phase 2
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Ixazomib Citrate, Lenalidomide
Study Phase: Phase 3
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: July 29, 2024
Intervention Type: Drug
Study Drug: Uproleselan
Study Phase: Phase 3
View 5 Less Clinical Trials

24 Total Publications

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 25, 2025
Similar Doctors
Expertise in
10
conditions
Dr. James George
Hematology
Expertise in
10
conditions
Dr. James George
Hematology
825 Ne 10th St, Oupb 5200, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-8299
Languages Spoken:
English
See accepted insurances

James George is a Hematologist in Oklahoma City, Oklahoma. Dr. George is highly rated in 10 conditions, according to our data. His top areas of expertise are Thrombocytopenia, Blood Clots, Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, and Splenectomy.

Expertise in
16
conditions
Dr. Raid Aljumaily
Hematology | Oncology
Expertise in
16
conditions
Dr. Raid Aljumaily
Hematology | Oncology

Ou Health Partners Inc

800 Ne 10th St, Ouhp Stephenson Cancer C, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-4088
Languages Spoken:
English
See accepted insurances

Raid Aljumaily is a Hematologist and an Oncologist in Oklahoma City, Oklahoma. Dr. Aljumaily is highly rated in 16 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma.

Expertise in
43
conditions
Dr. Hassan Hatoum
Hematology | Oncology
Expertise in
43
conditions
Dr. Hassan Hatoum
Hematology | Oncology

Ou Health Partners Inc

800 Ne 10th St, Ouhp Stephenson Cancer C, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-4088
Languages Spoken:
English
See accepted insurances

Hassan Hatoum is a Hematologist and an Oncologist in Oklahoma City, Oklahoma. Dr. Hatoum is highly rated in 43 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Familial Pancreatic Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Khawandanah's expertise for a condition
ConditionClose
    View All 22 Advanced Conditions
    View All 41 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile